Package leaflet: Information for the patient Spravato 28 mg nasal spray, solution esketamine This medicine is subject to additio
![Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program | CNS Drugs Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program | CNS Drugs](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40263-020-00699-4/MediaObjects/40263_2020_699_Fig1_HTML.png)
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program | CNS Drugs
Package leaflet: Information for the patient Spravato 28 mg nasal spray, solution esketamine This medicine is subject to additio
![SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder](https://d1l0gza1nowsqe.cloudfront.net/wp-content/uploads/sites/4/2022/05/Spravato6001PPS0_620.jpg)
SPRAVATO®▽ approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder
![Janssen's Esketamine Nasal Spray Which Is Similar To the Illegal Opioid Ketamine Gets Approved in the EU - Thailand Medical News Janssen's Esketamine Nasal Spray Which Is Similar To the Illegal Opioid Ketamine Gets Approved in the EU - Thailand Medical News](https://www.thailandmedical.news/uploads/editor/files/Janssen%E2%80%99s%20Esketamine%20Nasal%20Spray(1).jpg)
Janssen's Esketamine Nasal Spray Which Is Similar To the Illegal Opioid Ketamine Gets Approved in the EU - Thailand Medical News
![SPRAVATO®▽ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1 - Neuro Central SPRAVATO®▽ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1 - Neuro Central](https://www.neuro-central.com/wp-content/uploads/2020/11/industry-update.png)
SPRAVATO®▽ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1 - Neuro Central
Package leaflet: Information for the patient Spravato 28 mg nasal spray, solution esketamine This medicine is subject to additio
New Safety Data Suggests SPRAVATO®▽ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
Package leaflet: Information for the patient Spravato 28 mg nasal spray, solution esketamine This medicine is subject to additio
![Esketamine nasal spray that may be able to improve depression in those with suicidal thoughts approved by the FDA' | The US Sun Esketamine nasal spray that may be able to improve depression in those with suicidal thoughts approved by the FDA' | The US Sun](https://www.the-sun.com/wp-content/uploads/sites/6/2020/08/JF-US-WONDER-DRUG-COMP.jpg?strip=all&quality=100&w=1080&h=1000&crop=1)
Esketamine nasal spray that may be able to improve depression in those with suicidal thoughts approved by the FDA' | The US Sun
![Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study | Neuropsychopharmacology Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study | Neuropsychopharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41386-023-01577-5/MediaObjects/41386_2023_1577_Fig1_HTML.png)